N atural killer cells were originally described for their ability to kill target cells without prior stimulation (1) . It is currently recognized that these cells have potent antileukemic and antiviral activities (2, 3) . Human NK cells are identified by the CD3 2 CD56 + phenotype. Different NK cell subpopulations are determined according to the presence and density of CD56 and CD16 (FcgRIII) surface molecules. Lowdensity CD56 (CD56 dim ) subsets constitute .90% of peripheral blood NK cells, which also express perforin and killer Ig-like receptors (KIR). These cells, which express the CD16 marker, are involved in Ab-dependent cellular cytotoxicity (ADCC). The subset of CD56 bright NK cells, which are rare in blood but predominant in lymph nodes and other tissues, do not express perforin and KIR (4) . This CD56 bright subset exhibits immunoregulatory functions through the secretion of various cytokines (i.e., IFN-g, TNF-a, or IL-10) in response to monokine stimulation. In contrast, the CD56 dim cells are highly cytotoxic and preferentially produce cytokines after recognition of target cells (5, 6 (12) (13) (14) . The CD56 bright NK cells are the first lymphocytes, which appear following hematopoietic stem cell transplantations (HSCT) (15) (16) (17) (18) . Thus, HSCT is a good in vivo model to study hematopoietic cell differentiation, in particular NK cells. Dulphy et al. (15) have recently described an unusual CD56 bright CD16
+ subpopulation that was transiently increased 3 mo after identical HSCT. This subset was originally described in healthy individuals (19) .
The aim of the current study was to describe more precisely the CD56 bright CD16
+ NK subset and determine its role during NK cell differentiation. Our analysis of their function, phenotype, and frequencies during aging or after unrelated cord blood transplantation (UCBT), together with in vitro NK differentiation studies, strongly suggest that the CD56 
Materials and Methods

Patients and donors
Twenty-five patients (median age 43.5 y) underwent UCBT between 2005 and 2008 at either the Pitié-Salpêtrière or Hôtel Dieu hospitals (Paris, France) for high-risk hematopoietic malignancies. The cohort of these patients, mainly of Caucasian origin (24 out of 25), was previously described (18) . Briefly, acute myeloid leukemia was the most common diagnosis (14 out of 25). All patients received a reduced-intensity conditioning regimen; 20 patients received the Minneapolis protocol containing cyclophosphamide 50 mg/kg at day 6, fludarabine 200 mg/m 2 for 5 d, and total body irradiation 2 Gy. For the last five patients, total body irradiation was replaced by 140 mg/m 2 melphalan. Cyclosporine and mycophenolate mofetyl were given 3 d before transplantation to intensify the immunosuppressive conditioning and prevent graft-versus-host disease. Generic HLA-A, HLA-B, and allelic HLA-DR typing was used in the matching strategy; most of the cord blood pairs were 4 out of 6 matches. Adult controls and cord blood samples were obtained, respectively, from the Etablissement Français du sang and the obstetrics department of the Pitié-Salpêtrière Hospital. All adult donors used for the phenotyping; functional and differentiation assays were aged between 18 and 60 y old. The rheumatology and gerontology departments of Pitié-Salpêtrière or Charles-Foix Hospitals furnished 33 samples from individuals aged $60 y, 17 aged 60-80 y (mean age 68.8 6 7.2 y), and 26 .80 y (mean age 87.1 6 4.9 y). All volunteers affirmatively stated, and their medical records confirmed, that they had no infectious, malignant, or autoimmune diseases during the 6 mo before the study and were without acute illnesses at the time of the sampling, but could present treatment for classical age-related pathologies as previously described (20) . Patients and donors provided informed consent in compliance with the ethics committee guidelines before peripheral blood samples were collected for the study.
Flow cytometry
Phenotypes were realized on whole blood. Cells were stained using the appropriate Ab mixture + , and CD56 + T cell subsets were sorted on an FACSAria (BD Biosciences) after staining with CD3-ECD (UCHT1; Beckman Coulter), CD4-PE (13B8.2; Beckman Coulter), CD8-FITC (T8; Beckman Coulter), and CD56-PC7 (N901; Beckman Coulter).
NK degranulation, ADCC, and cytolytic assays NK cell subset's cytolytic activity was assessed in standard 4-h [ 51 Cr] release assays against K562 or RAJI target cells with a 5:1 E:T ratio, as described (18) . ADCC experiments were performed against RAJI cells in the presence of 1 mg/ml anti-CD20 (rituximab; Roche). Degranulation assays were tested by CD107a-PC5 (H4A3; BD Biosciences) detection, as described (18) . Importantly, staining with the nonblocking anti-CD16 mAb VEP13 clone was performed before the CD107a assays.
Intracellular analysis of IFN-g production
PBMCs were first stained with CD16-FITC (clone VEP-13) and incubated for 6 h in the presence of 10 ng/ml IL-12 and 100 ng/ml IL-18 at 37˚C and 5% CO 2 . Cells were thereafter stained for CD3 and CD56, fixed (BD Cell Fix; BD Biosciences), and permeabilized (PBS/0.5% BSA/0.1% saponin) before staining for intracellular IFN-g (B27; BD Biosciences) expression. Acquisitions were performed on an LSRII (BD Biosciences) flow cytometer. + CD56 + lymphocyte T subsets. When specified, T cells were physically separated from NK cells with transwells (eight-well strip insert; Nunc). Cytokines and culture media were renewed every 2 or 3 d. NK cells were characterized at indicated time points using the same panel of Abs as those used for the cell sorting.
In vitro differentiation assays
Statistics
All statistical analyses were performed using Prism 5 software (GraphPad, San Diego, CA). Nonparametric Wilcoxon and Mann-Whitney tests were used for paired and unpaired data comparisons, respectively. Repeatedmeasures ANOVA with Tukey posttest for p value calculation were performed for multiple comparisons of paired data. Kruskal-Wallis test with the Dunn posttest for p value calculation was performed for multiple comparisons of independent groups. Significance is defined by a p value ,0.05 using two-tailed tests. *p , 0.05, **p , 0.01, ***p , 0.001.
Results
Kinetics of CD56
bright CD16 + NK cell repopulation following UCBT
The phenotypic characterization of NK cells following UCBT revealed that the CD56 bright CD16 + NK cell subset is highly expressed among whole NK cells following the transplantation. The CD56 bright CD16 2 subset increases very rapidly just after neutrophil engraftment, at 1-mo post-UCBT, and then gradually decreases during the time examined (Fig. 1A) . Interestingly, CD56 bright CD16 + NK cells were present at 1 mo posttransplantation, but increased to their maximum frequency 2 mo after UCBT and remained stable during the following 12 mo (Fig. 1B) To characterize functional properties of NK cells, regardless of CD16 expression, preliminary experiments were performed to determine appropriate experimental conditions. Indeed, CD16 is quickly downmodulated after encounter with K562 or RAJI target cells, which renders discrimination of the different subsets after degranulation assays impossible (Supplemental Fig. 3) (21, 22) . Furthermore, the anti-CD16 3G8 clone is a blocking Ab of ADCC, which does not allow cell sorting for [ 51 Cr] release assays (data not shown). For these reasons, we performed all experiments in the presence of the anti-CD16 VEP13 clone, which does not block ADCC. Fig. 3A shows that in the presence of the anti-CD16 mAb VEP13 clone, the expression of CD16 on NK cells is preserved after encountering of target cells, which allows analysis of NK subsets after degranulation assays (Fig. 3A) .
We next compared the cytolytic capacities of CD56 3C) . The high lytic ability of CD56 bright CD16
+ cells was confirmed by ADCC assays against RAJI cells covered with anti-CD20 mAb (rituximab). Indeed, both in degranulation and chromium release assays, CD56 bright CD16
+ cells were as efficient as CD56 dim CD16 + cells (Fig. 3E, 3F) 2 cells acquired CD16 (Fig. 4A , middle panels).
To determine the role of the cell-cell contact requirements, similar experiments were performed in transwell plates. As shown in Fig.  4A (right panels), in the absence of cellular contacts, the CD56 bright CD16 2 NK cells showed reduced CD16 acquisition.
We next evaluated the efficacy of CD4 + , CD8 + , and CD3 + CD56 + T cell subsets to induce CD16 acquisition by CD56 bright CD16 2 NK cells. In the presence of all of these CD3 + T cell subsets, similar proportions of NK cells expressing CD16 were observed (Fig. 4B) . Importantly, kinetic studies revealed that in the presence CD3 + T cells, expression of CD16 increased until day 14, when it reached a maximum level of between 25 and 30% (Fig. 4C) . In an attempt to increase CD16 + expression on NK cells, we next performed experiments in the presence of autologous dendritic cells (DC). Immature DCs (iDC) were derived from purified CD14 monocytes in the presence of IL-4 and GM-CSF, whereas mature DCs (mDC) were obtained from iDC pulsed with LPS or bacillus Calmette-Guérin. Both iDC and mDC were cultured with or without CD3 + T cells to induce CD16 expression on CD56 bright CD16 2 cells. Unfortunately, the presence of iDC or mDC had no effect on CD16 expression (data not shown).
To determine the differentiation state of CD16 + cells generated in vitro in the presence of CD3 + T cells, we studied the expression of major differentiation markers including KIR, NKG2A, ILT-2, and CD62L (Fig. 4D) . We demonstrated that CD16 + NK cells expressed a significantly higher level of KIR than the CD16 2 subset at all culture times examined, although this level remains low (∼10%). Concomitantly, NKG2A remained highly expressed on both subsets, whereas CD62L and ILT-2 decreased and increased, respectively, during the culture, independently of CD16 expression. Fig. 5B) . In contrast, (20, 23) . We showed that the percentage of CD56 bright NK cells expressing CD16 increases linearly with aging (Fig. 6A) . Indeed, when comparing people's aging with ,60 and .80 y old, we observed that older persons expressed 2-3-fold more CD16 in their CD56 bright compartment (p , 0.001). Thus, younger donors expressed CD16 on ∼25% of CD56 bright NK cells, whereas elderly people .80 y old expressed this marker on ∼50-75% of these cells. Fig. 6B 2 precursor cells, as previously described for T and B cells (25) . It was observed in older individuals both increasing of soluble IL-2R, which downregulated IL-2 activity (26), and IL-12p40 homodimers, which could act as an IL-12 antagonist (27) . This could suggest that the disturbance of specific cytokine signaling could partially block the final maturation of NK cells at a stage of CD56 bright CD16 + NK cells, which are accumulated in older subjects.
To minimize this effect due to particular clinical situations, the main experiments of this study were performed in healthy donors. The CD56 bright CD16 + NK cell subpopulation represents 1. (34) , is similarly expressed on CD16 2 and CD16 + NK cells after in vitro culture. This could reflect long-lasting activation/proliferation instead of a differentiation of cells, as previously shown for CD62L (35) . As expected, purified CD56 bright CD16 + NK cells retained a greater ability to express CD16 and KIR after culture in the presence of autologous IL-2-activated CD3 + T cells. Indeed, despite a decreased expression of CD16 at early time points of the culture, CD16 was expressed by .80% of NK cells after 28 d of culture. Early decreases in CD16 expression might be explained by an extracellular metalloprotease activity, as previously described (21, 22) .
Recently, we and others suggested that the CD56 dim subset is composed from several differentiation stages, but only few studies investigated the CD56 bright subset (36) (37) (38) 2 NK cells into a later stage that expresses CD16
and is highly functional.
